Study of SGM-1019 in Patients With Nonalcoholic Steatohepatitis (NASH)
NCT ID: NCT03676231
Last Updated: 2019-07-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
9 participants
INTERVENTIONAL
2019-01-18
2019-05-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Randomized, Double-blind, Placebo-controlled Study of ZSP1601 in Adult Subjects With Nonalcoholic Steatohepatitis (NASH)
NCT05692492
Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Participants With Nonalcoholic Steatohepatitis (NASH)
NCT02854605
A Safety, Tolerability, Efficacy, and Pharmacokinetics Study of HEC96719 in Subjects With Non-Cirrhotic Non-Alcoholic Steatohepatitis
NCT05397379
Study of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (NASH)
NCT04906421
Study to Evaluate MET642 in Patients With NASH
NCT04773964
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
High-dose SGM-1019
SGM-1019
Active
Low-dose SGM-1019
SGM-1019
Active
Placebo
Placebo
Inactive
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SGM-1019
Active
Placebo
Inactive
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 18 to 75 years, inclusive
* Elevated ALT
* F1-F3 NASH
* BMI ≥ 25
Exclusion Criteria
* Poorly controlled type 2 diabetes
* Hepatic decompensation
* Chronic liver disease
* Planned surgeries/procedures
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Second Genome
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Matthew W McClure, M.D.
Role: STUDY_DIRECTOR
Second Genome
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Second Genome Clinical Site 405
Chandler, Arizona, United States
Second Genome Clinical Site 406
Tucson, Arizona, United States
Second Genome Clinical Site 403
Panorama City, California, United States
Second Genome Clinical Site 409
Lakewood Rch, Florida, United States
Second Genome Clinical Site 410
Flowood, Mississippi, United States
Second Genome Clinical Site 404
Kansas City, Missouri, United States
Second Genome Clinical Site 408
Fayetteville, North Carolina, United States
Second Genome Clinical Site 407
Clarksville, Tennessee, United States
Second Genome Clinical Site 402
Austin, Texas, United States
Second Genome Clinical Site 401
San Antonio, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SGM-1019-102
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.